Deutsche Bank Boosts PT on Biogen (BIIB) to $170 on Tysabri Deal
Tweet Send to a FriendGet Alerts BIIB Hot Sheet
Price: $226.85 -0.5%
Rating Summary:
17 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
17 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade BIIB Now!
Deutsche Bank raised its price target on Buy-rated Biogen (NASDAQ: BIIB) from $160 to $170 following the news the company acquired 100% rights for Tysabri from ELAN (NYSE: ELN) for an upfront payment of $3.25B and contingent royalty payments based on global net sales.
"Higher economics with this new deal should lead to significant EPS accretion and we calculate this deal to be NPV positive for BIIB," the analyst states. The firm calculates DCF impact of this deal at $6/sh on DCF, they are also decreasing SG&A by $50M every year increasing DCF by another $4/sh.
Deutsche Bank models the deal to be $0.60/sh accretive in 2013 and $0.79/sh accretive in 2014. Per BIIB, 2013 and 2014 accretion will be in $0.50-$0.60 and $0.65-$0.80 range respectively.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $157.36 yesterday, with a 52 week range of $114.53-$158.39.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
"Higher economics with this new deal should lead to significant EPS accretion and we calculate this deal to be NPV positive for BIIB," the analyst states. The firm calculates DCF impact of this deal at $6/sh on DCF, they are also decreasing SG&A by $50M every year increasing DCF by another $4/sh.
Deutsche Bank models the deal to be $0.60/sh accretive in 2013 and $0.79/sh accretive in 2014. Per BIIB, 2013 and 2014 accretion will be in $0.50-$0.60 and $0.65-$0.80 range respectively.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $157.36 yesterday, with a 52 week range of $114.53-$158.39.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- UPDATE: Leerink Swann Upgrades Bristol-Myers Squibb Co. (BMY) to Outperform
- Supernus (SUPN) PT Trimmed at Jefferies, But Survey Shows Significant Market Opportunity
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Deutsche Bank
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
